Beacon Therapeutics Secures $35M in Series A Funding to Advance Ophthalmic Gene Therapy Portfolio

Roan Therapeutics is thrilled to announce that it has successfully raised $35 million in a recent funding round, which will significantly accelerate its mission to save and restore the vision of patients suffering from a variety of retinal diseases. Founded in 2023, Beacon Therapeutics is an innovative ophthalmic gene therapy company focused on tackling both prevalent and rare conditions that threaten sight. The company's flagship development candidate, AGTC-501, is currently in Phase II clinical trials aimed at addressing X-linked retinitis pigmentosa (XLRP), a severe inherited disease that ultimately leads to vision loss, primarily in boys and young men. With XLRP largely attributed to mutations in the RPGR gene, AGTC-501 aims to express the full-length RPGR protein, effectively combating photoreceptor damage and preventing gradual sight deterioration. In addition to XLRP, Beacon Therapeutics is advancing two promising preclinical programs targeting dry age-related macular degeneration (AMD) and cone-rod dystrophy (CRD), further expanding its therapeutic reach. The funding, led by high-profile investors including Syncona, Forbion, and Oxford Science Enterprises, will enhance the company’s proprietary target generation technology platform, which is designed to identify and screen secreted proteins in the ophthalmology space, paving the way for even more groundbreaking therapies. As we move forward, this investment not only bolsters our research and development initiatives but also brings us a step closer to transforming the lives of countless individuals facing the despair of vision loss. Stay tuned as we continue on this exciting journey towards innovative ocular therapies and groundbreaking advancements in gene therapy.